Theriva Biologics, INC 10-Q quarterly reports

Theriva Biologics, Inc. reported continued operating losses and substantial accumulated deficit in its Q2 2026 10-Q filing, raising significant doubts about its ability to continue as a going concern, despite positive clinical trial updates.

Theriva Biologics reports a significant decrease in R&D expenses for Q1 2026, driven by clinical trial completions and a new licensing agreement for SYN-020, while facing ongoing going concern uncertainties.

Theriva Biologics reports Q3 2025 results, extending cash runway into Q1 2027 and advancing its lead oncology candidate VCN-01 with positive clinical data.

Theriva Biologics announced positive clinical trial results for its lead oncology candidate VCN-01 in pancreatic cancer and retinoblastoma, while facing significant liquidity challenges.

Theriva Biologics reports a net loss for Q1 2025 but highlights positive topline outcomes from its VIRAGE Phase 2b clinical trial for VCN-01 in pancreatic cancer.

Theriva Biologics reported its third quarter 2024 financial results and provided updates on its clinical development programs, including the completion of enrollment in a Phase 2 trial for pancreatic cancer.

Theriva Biologics reported its second quarter 2024 financial results, including a goodwill impairment charge, while also highlighting clinical advancements in its oncology programs.

Theriva Biologics reported its first quarter 2024 financial results and provided an update on its clinical development programs, including its lead oncology candidate VCN-01.